You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameValproic Acid
Accession NumberDB00313  (APRD00066, APRD00256, DB00510)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Valproic acid, supplied as the sodium salt valproate semisodium or divalproex sodium, is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (CAS number: 76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.

Structure
Thumb
Synonyms
2-n-propyl-n-valeric acid
2-PROPYL-pentanoic acid
2-Propylpentanoic Acid
2-Propylvaleric Acid
4-heptanecarboxylic acid
Acide valproique
Acido valproico
Acidum valproicum
Depakene
di-n-propylacetic acid
Di-N-propylessigsaeure
Di-n-propylessigsäure
Dipropylacetic acid
DPA
n-DPA
Valproate
VALPROIC acid
Valproinsaeure
Valproinsäure
VPA
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Depaconinjection100 mg/mLintravenousAbb Vie Inc.1996-12-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakenesolution250 mg/5mLoralAbb Vie Inc.1978-02-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakenesolution50 mgoralBgp Pharma Ulc1978-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Depakenecapsule, liquid filled250 mg/1oralAbb Vie Inc.1978-02-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakenecapsule250 mgoralBgp Pharma Ulc1978-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Depakene Cap 500mgcapsule (enteric-coated)500 mgoralAbbott Laboratories, Limited1981-12-312007-05-11Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Depakotetablet, extended release250 mg/1oralPhysicians Total Care, Inc.2006-02-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakotetablet, delayed release500 mg/1oralAbb Vie Inc.1983-03-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakotetablet, delayed release500 mg/1oralREMEDYREPACK INC.2014-07-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakotetablet, delayed release250 mg/1oralAbb Vie Inc.1983-03-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakotetablet, delayed release250 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakotetablet, delayed release125 mg/1oralAbb Vie Inc.1983-03-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakotetablet, extended release250 mg/1oralRebel Distributors Corp2010-06-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakotetablet, delayed release250 mg/1oralREMEDYREPACK INC.2014-12-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakotetablet, extended release500 mg/1oralRebel Distributors Corp2010-06-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakotetablet, extended release500 mg/1oralCardinal Health2010-06-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakotetablet, extended release500 mg/1oralPhysicians Total Care, Inc.2003-11-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakotecapsule125 mg/1oralCardinal Health2010-06-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakote ERtablet, extended release500 mg/1oralAphena Pharma Solutions Tennessee, Llc2000-08-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakote ERtablet, extended release500 mg/1oralbryant ranch prepack2010-06-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakote ERtablet, extended release250 mg/1oralAbb Vie Inc.2000-08-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakote ERtablet, extended release500 mg/1oralAbb Vie Inc.2000-08-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Depakote Sprinklescapsule125 mg/1oralAbb Vie Inc.1989-09-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Deproic Syrupsyrup250 mgoralTechnilab Pharma Inc.1998-06-022006-07-28Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Divalproextablet (enteric-coated)500 mgoralSanis Health Inc2013-02-13Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Divalproextablet (enteric-coated)250 mgoralSanis Health Inc2013-02-13Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Divalproextablet (enteric-coated)125 mgoralSanis Health Inc2013-02-13Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Divalproex Sodium Delayed Release (sprinkle)capsule125 mg/1oralSandoz Inc.2015-08-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Extended Releasetablet, extended release250 mg/1oralZydus Pharmaceuticals USA Inc2000-08-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Extended Releasetablet, extended release500 mg/1oralZydus Pharmaceuticals USA Inc2013-08-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Extended-releasetablet, extended release500 mg/1oralTYA Pharmaceuticals2013-08-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Extended-releasetablet, extended release250 mg/1oralTYA Pharmaceuticals2000-08-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Extended-releasetablet, extended release500 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex-125tablet (enteric-coated)125 mgoralPro Doc Limitee2001-08-22Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Divalproex-250tablet (enteric-coated)250 mgoralPro Doc Limitee2001-08-22Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Divalproex-500tablet (enteric-coated)500 mgoralPro Doc Limitee2001-08-22Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-divalproextablet (enteric-coated)125 mgoralDominion Pharmacal2002-04-15Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-divalproextablet (enteric-coated)500 mgoralDominion Pharmacal2002-04-15Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-divalproextablet (enteric-coated)250 mgoralDominion Pharmacal2002-04-15Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-valproic Acidcapsule250 mgoralDominion Pharmacal1998-04-25Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-valproic Acid E.C.capsule (enteric-coated)500 mgoralDominion Pharmacal1998-10-22Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Dom-valproic Acid Syrupsyrup250 mgoralDominion Pharmacal1999-03-08Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Epiject I.V.liquid500 mgintravenousAbbott Laboratories, Limited2000-09-012007-10-05Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Epivaltablet (enteric-coated)500 mgoralBgp Pharma Ulc1984-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Epivaltablet (enteric-coated)250 mgoralBgp Pharma Ulc1984-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Epivaltablet (enteric-coated)125 mgoralBgp Pharma Ulc1984-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Epival ERtablet (extended-release)500 mgoralAbbott Laboratories, Limited2000-11-132008-06-06Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ftp-valproic Acidcapsule250 mgoralFtp Pharmacal Inc.1998-10-092004-08-03Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-divalproextablet (delayed-release)500 mgoralMylan Pharmaceuticals Ulc2005-03-04Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-divalproextablet (delayed-release)250 mgoralMylan Pharmaceuticals Ulc2005-03-04Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-divalproextablet (delayed-release)125 mgoralMylan Pharmaceuticals Ulc2005-03-04Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-valproiccapsule250 mgoralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-valproiccapsule (enteric-coated)500 mgoralTeva Canada Limited1997-01-07Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-valproiccapsule250 mgoralTeva Canada Limited1995-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-divalproex 125mgtablet (enteric-coated)125 mgoralNu Pharm Inc1999-01-202012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-divalproex 250mgtablet (enteric-coated)250 mgoralNu Pharm Inc1999-01-202012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-divalproex 500mgtablet (enteric-coated)500 mgoralNu Pharm Inc1999-01-202012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-valproiccapsule250 mgoralNu Pharm Inc1998-07-292012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-valproic Syrupsyrup50 mgoralNu Pharm IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Penta-valproic Capsulescapsule250 mgoralPentapharm Ltd.Not applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PHL-divalproextablet (enteric-coated)500 mgoralPharmel Inc2007-10-25Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PHL-divalproextablet (enteric-coated)250 mgoralPharmel Inc2007-10-25Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PHL-divalproextablet (enteric-coated)125 mgoralPharmel Inc2007-08-01Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PHL-valproic Acidcapsule250 mgoralPharmel Inc2004-12-02Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PHL-valproic Acidsyrup250 mgoralPharmel Inc1998-09-03Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PHL-valproic Acid E.C.capsule (enteric-coated)500 mgoralPharmel Inc2004-12-06Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-divalproex (125mg)tablet (enteric-coated)125 mgoralPharmascience Inc2001-08-03Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-divalproex (250mg)tablet (enteric-coated)250 mgoralPharmascience Inc2001-08-03Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-divalproex (500mg)tablet (enteric-coated)500 mgoralPharmascience Inc2001-08-03Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-valproic Acidcapsule250 mgoralPharmascience Inc1997-02-27Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-valproic Acidsyrup250 mgoralPharmascience Inc1997-11-20Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
PMS-valproic Acid E.C.capsule (enteric-coated)500 mgoralPharmascience Inc1996-12-13Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-valproiccapsule (enteric-coated)500 mgoralTeva Canada Limited1997-08-28Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-valproiccapsule250 mgoralTeva Canada Limited1996-11-04Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-valproic - Ecc 500mgcapsule (enteric-coated)500 mgoralRatiopharm Inc Division Of Teva Canada Limited1996-07-172010-08-02Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-valproic 50mg/ml Syrupsyrup50 mgoralRatiopharm Inc Division Of Teva Canada Limited1998-01-192015-10-26Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Ratio-valproic-cap 250mgcapsule250 mgoralRatiopharm Inc Division Of Teva Canada Limited1995-12-312014-09-19Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz Valproiccapsule250 mgoralSandoz Canada Incorporated2000-01-28Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sandoz Valproiccapsule (enteric-coated)500 mgoralSandoz Canada Incorporated2000-01-282008-08-07Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-divalproextablet (enteric-coated)500 mgoralTeva Canada Limited1999-04-14Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-divalproextablet (enteric-coated)250 mgoralTeva Canada Limited1999-04-14Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Teva-divalproextablet (enteric-coated)125 mgoralTeva Canada Limited1999-04-14Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Valproic-250capsule250 mgoralPro Doc Limitee1998-11-252012-07-23Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-divalproextablet (enteric-coated)500 mgoralApotex Inc1999-03-24Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-divalproextablet (enteric-coated)250 mgoralApotex Inc1999-03-24Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-divalproextablet (enteric-coated)125 mgoralApotex Inc1999-03-24Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-valproiccapsule250 mgoralApotex Inc1998-06-01Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Apo-valproic Syrupsyrup50 mgoralApotex Inc1998-07-15Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Divalproex Sodiumtablet, delayed release500 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-03-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumcapsule125 mg/1oralDr. Reddy's Laboratories Ltd2009-01-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralREMEDYREPACK INC.2013-02-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralCadila Healthcare Limited2010-06-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralBlue Point Laboratories2013-10-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumcapsule, coated pellets125 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-01-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumcapsule, delayed release125 mg/1oralMylan Pharmaceuticals Inc.2011-03-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralTeva Pharmaceuticals USA Inc2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralCardinal Health2011-07-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, extended release250 mg/1oralREMEDYREPACK INC.2011-07-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release250 mg/1oralAurobindo Pharma Limited2014-06-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralAmerican Health Packaging2014-10-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralMc Kesson Contract Packaging2011-08-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralCitron Pharma LLC2011-04-212016-07-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralLake Erie Medical DBA Quality Care Products LLC2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralMajor Pharmaceuticals2009-08-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumcapsule125 mg/1oralMylan Institutional Inc.2012-07-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-03-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release250 mg/1oralNorth Star Rx Llc2014-06-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralClinical Solutions Wholesale2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, extended release250 mg/1oralAmneal Pharmaceuticals of New York, LLC2015-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralMylan Pharmaceutical Inc.2009-04-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, extended release250 mg/1oralREMEDYREPACK INC.2010-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralSun Pharmaceutical Industries Limited2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralCardinal Health2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralDr. Reddy's Laboratories Ltd2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, extended release500 mg/1oralREMEDYREPACK INC.2011-07-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralAurobindo Pharma Limited2011-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralAmerican Health Packaging2014-10-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralMc Kesson Contract Packaging2011-10-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralWockhardt Limited2008-07-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralAidarex Pharmaceuticals LLC2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralREMEDYREPACK INC.2015-03-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release250 mg/1oralMajor Pharmaceuticals2009-08-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralCardinal Health2014-11-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralLupin Pharmaceuticals, Inc.2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralClinical Solutions Wholesale, Llc2011-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralTYA Pharmaceuticals2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-02-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralMylan Pharmaceuticals Inc.2009-02-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralSun Pharmaceutical Industries Limited2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralCardinal Health2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralPhysicians Total Care, Inc.2009-11-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralMylan Institutional Inc.2009-06-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralAurobindo Pharma Limited2011-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralAmerican Health Packaging2013-11-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralMc Kesson Contract Packaging2011-01-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralWockhardt Limited2008-07-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-01-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralREMEDYREPACK INC.2014-11-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralUpsher Smith Laboratories, Inc.2014-03-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralCardinal Health2009-02-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, extended release250 mg/1oralREMEDYREPACK INC.2011-07-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralLupin Pharmaceuticals, Inc.2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralClinical Solutions Wholesale, Llc2011-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralTYA Pharmaceuticals2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release250 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-02-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release250 mg/1oralMylan Pharmaceuticals Inc.2009-01-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralSun Pharmaceutical Industries Limited2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralPhysicians Total Care, Inc.2009-10-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralMylan Institutional Inc.2009-09-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralContract Pharmacy Services Pa2010-08-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralWockhardt Limited2008-07-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release250 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-01-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-08-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralUnichem Pharmaceuticals (USA), Inc.2011-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralREMEDYREPACK INC.2014-10-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralUpsher Smith Laboratories, Inc.2014-03-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralCardinal Health2009-08-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumcapsule, coated pellets125 mg/1oralCadila Healthcare Limited2009-01-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralTYA Pharmaceuticals2014-06-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralUpsher Smith Laboratories, Inc.2011-01-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralMedsource Pharmaceuticals2011-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralWatson Pharma, Inc.2011-02-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralCardinal Health2011-07-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralUnit Dose Services2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralContract Pharmacy Services Pa2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralLupin Pharmaceuticals, Inc.2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release250 mg/1oralGlobal Pharmaceuticals, Division of Impax Laboratories Inc.2009-08-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralUnichem Pharmaceuticals (USA), Inc.2011-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release250 mg/1oralREMEDYREPACK INC.2014-10-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralUpsher Smith Laboratories, Inc.2014-03-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralREMEDYREPACK INC.2011-06-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralCadila Healthcare Limited2013-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralAvera Mc Kennan Hospital2015-03-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralUpsher Smith Laboratories, Inc.2011-01-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralAphena Pharma Solutions Tennessee, Llc2009-02-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralDIRECT RX2015-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralContract Pharmacy Services Pa2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralCarilion Materials Management2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumcapsule125 mg/1oralMc Kesson Contract Packaging2011-12-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralCitron Pharma LLC2014-10-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralWOCKHARDT USA LLC2008-07-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralTeva Pharmaceuticals USA Inc2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralUnichem Pharmaceuticals (USA), Inc.2011-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralREMEDYREPACK INC.2014-08-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, extended release500 mg/1oralDr. Reddy's Laboratories Ltd2013-08-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralREMEDYREPACK INC.2011-03-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release250 mg/1oralCadila Healthcare Limited2013-07-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumcapsule, coated pellets125 mg/1oralAmerican Health Packaging2009-04-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralZydus Pharmaceuticals (USA) Inc.2013-01-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralDIRECT RX2014-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, extended release500 mg/1oralMajor Pharmaceuticals2013-08-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralAurobindo Pharma Limited2014-10-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralMc Kesson Contract Packaging2011-10-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralCitron Pharma LLC2011-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralWOCKHARDT USA LLC2008-07-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralUpsher Smith Laboratories, Inc.2011-01-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralPd Rx Pharmaceuticals, Inc.2009-08-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralDr. Reddy's Laboratories Ltd2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralMylan Institutional Inc.2009-02-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release250 mg/1oralBlue Point Laboratories2013-10-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-03-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralCadila Healthcare Limited2010-06-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-03-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralMylan Pharmaceutical Inc.2009-04-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, extended release250 mg/1oralDr. Reddy's Laboratories Ltd2013-08-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralCadila Healthcare Limited2010-06-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release250 mg/1oralAmerican Health Packaging2013-11-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release250 mg/1oralZydus Pharmaceuticals (USA) Inc.2013-01-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralbryant ranch prepack2011-10-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralTeva Pharmaceuticals USA Inc2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumcapsule, coated pellets125 mg/1oralCardinal Health2009-04-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralREMEDYREPACK INC.2011-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralAurobindo Pharma Limited2014-06-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release250 mg/1oralMc Kesson Contract Packaging2012-02-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralCitron Pharma LLC2011-04-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralWOCKHARDT USA LLC2008-07-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumcapsule125 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-01-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralDIRECT RX2015-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, extended release250 mg/1oralMajor Pharmaceuticals2013-08-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralDr. Reddy's Laboratories Ltd2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release250 mg/1oralMylan Institutional Inc.2009-02-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-03-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, film coated, extended release500 mg/1oralNorth Star Rx Llc2014-06-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralClinical Solutions Wholesale2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, extended release500 mg/1oralAmneal Pharmaceuticals of New York, LLC2015-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release125 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-03-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release250 mg/1oralMylan Pharmaceutical Inc.2009-04-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumtablet, delayed release500 mg/1oralREMEDYREPACK INC.2011-04-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Delayed Releasetablet, delayed release250 mg/1oralREMEDYREPACK INC.2011-04-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Delayed Releasetablet, delayed release500 mg/1oralREMEDYREPACK INC.2010-11-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Delayed Releasetablet, delayed release500 mg/1oralREMEDYREPACK INC.2011-04-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Delayed-releasetablet, film coated250 mg/1oralbryant ranch prepack2009-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Delayed-releasetablet, film coated500 mg/1oralQualitest Pharmaceuticals2009-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Delayed-releasetablet, film coated250 mg/1oralQualitest Pharmaceuticals2009-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Delayed-releasetablet, film coated500 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Delayed-releasetablet, film coated125 mg/1oralQualitest Pharmaceuticals2009-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Delayed-releasetablet, delayed release500 mg/1oralT Wi Pharmaceuticals, Inc.2011-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Drtablet, delayed release250 mg/1oralCardinal Health2009-10-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Drtablet, delayed release500 mg/1oralRebel Distributors Corp2009-10-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Drtablet, delayed release particles500 mg/1oralSTAT Rx USA LLC2008-07-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Drtablet, delayed release500 mg/1oralAmerican Health Packaging2009-10-142016-05-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Drtablet, delayed release250 mg/1oralAmerican Health Packaging2009-10-142016-05-31Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Drtablet, delayed release500 mg/1oralCardinal Health2009-10-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Drtablet, delayed release250 mg/1oralRebel Distributors Corp2009-10-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Drtablet, delayed release500 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2009-10-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Drtablet, delayed release125 mg/1oralRebel Distributors Corp2009-10-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium ERtablet, film coated, extended release500 mg/1oralWOCKHARDT USA LLC2009-08-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium ERtablet, film coated, extended release250 mg/1oralWOCKHARDT USA LLC2009-02-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium ERtablet, film coated, extended release500 mg/1oralWockhardt Limited2009-08-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium ERtablet, film coated, extended release250 mg/1oralWockhardt Limited2009-02-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium ERtablet, film coated, extended release500 mg/1oralbryant ranch prepack2009-08-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Extended Releasetablet, extended release500 mg/1oralREMEDYREPACK INC.2010-11-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Extended Releasetablet, extended release500 mg/1oralREMEDYREPACK INC.2011-05-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Extended-releasetablet, extended release500 mg/1oralAmerican Health Packaging2009-10-142015-12-29Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Extended-releasetablet, extended release250 mg/1oralAmerican Health Packaging2009-10-142015-12-29Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Extended-releasetablet, extended release500 mg/1oralPar Pharmaceutical, Inc.2009-08-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Extended-releasetablet, extended release250 mg/1oralPar Pharmaceutical, Inc.2009-02-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Extended-releasetablet, extended release500 mg/1oralCardinal Health2009-10-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodium Extended-releasetablet, extended release500 mg/1oralCardinal Health2009-08-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumdelayed-release Delayed-releasetablet, film coated500 mg/1oralAidarex Pharmaceuticals LLC2009-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Divalproex Sodiumdelayed-release Delayed-releasetablet, film coated250 mg/1oralREMEDYREPACK INC.2013-02-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproate Sodiuminjection100 mg/mLintravenousWest ward Pharmaceutical Corp2013-04-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproate Sodiuminjection, solution100 mg/mLintravenousFresenius Kabi USA, LLC2003-08-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproate Sodiuminjection500 mg/5mLintravenousWest ward Pharmaceutical Corp2010-02-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproiccapsule, liquid filled250 mg/1oralContract Pharmacy Services Pa2010-04-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproiccapsule, liquid filled250 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-09-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproiccapsule, liquid filled250 mg/1oralContract Pharmacy Services Pa2010-04-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproiccapsule, liquid filled250 mg/1oralPhysicians Total Care, Inc.1994-04-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproiccapsule, liquid filled250 mg/1oralActavis Pharma, Inc.2009-09-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproiccapsule, liquid filled250 mg/1oralClinical Solutions Wholesale2009-09-08Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidcapsule, liquid filled250 mg/1oralGolden State Medical Supply, Inc.2015-07-02Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidcapsule250 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1991-10-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidcapsule, liquid filled250 mg/1oralREMEDYREPACK INC.2015-12-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidcapsule, liquid filled250 mg/1oralRebel Distributors Corp1993-06-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidsolution250 mg/5mLoralPharmaceutical Associates, Inc.2005-04-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidsolution250 mg/5mLoralAtlantic Biologicals Corps1995-01-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidsolution250 mg/5mLoralPharmaceutical Associates, Inc.2005-04-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidcapsule, liquid filled250 mg/1oralCardinal Health2010-06-04Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidcapsule, liquid filled250 mg/1oralBanner Life Sciences Llc.2015-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidtablet250 mg/1oralREMEDYREPACK INC.2011-06-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidcapsule250 mg/1oralMylan Institutional Inc.2012-08-102015-12-29Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidsolution250 mg/5mLoralCaraco Pharmaceutical Laboratories, Ltd.2012-04-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidcapsule, liquid filled250 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2005-03-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidsolution250 mg/5mLoralQualitest Pharmaceuticals2006-10-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidsolution250 mg/5mLoralCardinal Health2003-12-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidsolution250 mg/5mLoralHi Tech Pharmacal Co., Inc.1995-01-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidcapsule250 mg/1oralUpsher Smith Laboratories, Inc1991-10-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidcapsule, liquid filled250 mg/1oralPliva Inc.1993-10-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidsolution500 mg/10mLoralPrecision Dose Inc.2007-01-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidsolution250 mg/5mLoralMorton Grove Pharmaceuticals, Inc.1995-04-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidcapsule250 mg/1oralUpsher Smith Laboratories, Inc.2011-10-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidsolution250 mg/5mLoralCardinal Health2005-04-11Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidsolution250 mg/5mLoralWatson Laboratories, Inc.1995-01-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidsolution250 mg/5mLoralPrecision Dose Inc.2003-12-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidcapsule250 mg/1oralCardinal Health2012-08-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidcapsule250 mg/1oralAphena Pharma Solutions Tennessee, Llc1991-10-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Valproic Acidcapsule250 mg/1oralSun Pharmaceutical Industries Limited2013-02-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
ConvulexNot Available
DepakineNot Available
DeprakineNot Available
EncorateNot Available
EpilimNot Available
ValcoteNot Available
ValparinNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Valproate Semisodium
76584-70-8
Thumb
  • InChI Key: MSRILKIQRXUYCT-UHFFFAOYSA-M
  • Monoisotopic Mass: 310.212004155
  • Average Mass: 310.4047
DBSALT000185
Valproate sodium
ThumbNot applicableDBSALT001257
Categories
UNII614OI1Z5WI
CAS number99-66-1
WeightAverage: 144.2114
Monoisotopic: 144.115029756
Chemical FormulaC8H16O2
InChI KeyInChIKey=NIJJYAXOARWZEE-UHFFFAOYSA-N
InChI
InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
IUPAC Name
2-propylpentanoic acid
SMILES
CCCC(CCC)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as methyl-branched fatty acids. These are fatty acids with an acyl chain that has a methyl branch. Usually, they are saturated and contain only one or more methyl group. However, branches other than methyl may be present.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassFatty acids and conjugates
Direct ParentMethyl-branched fatty acids
Alternative Parents
Substituents
  • Methyl-branched fatty acid
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Pharmacology
IndicationFor treatment and management of seizure disorders, mania, and prophylactic treatment of migraine headache. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome.
PharmacodynamicsThe relationship between plasma concentration and clinical response is not well documented. One contributing factor is the nonlinear, concentration dependent protein binding of valproate which affects the clearance of the drug. Thus, monitoring of total serum valproate cannot provide a reliable index of the bioactive valproate species. For patients with epilepsy, the therapeutic range is commonly considered to be 50 to 100 mcg/mL of total valproate. However, patients may be controlled at lower or higher doses.
Mechanism of actionValproic Acid dissociates to the valproate ion in the gastrointestinal tract and then binds to and inhibits GABA transaminase. The drug's anticonvulsant activity may be related to increased brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the CNS, by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. Valproic Acid may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels. It is also a histone deacetylase inhibitor. Valproic acid has also been shown to be an inhibitor of an enzyme called histone deacetylase 1 (HDAC1). HDAC1 is needed for HIV to remain in infected cells. A study published in August 2005 revealed that patients treated with valproic acid in addition to highly active antiretroviral therapy (HAART) showed a 75% reduction in latent HIV infection.
AbsorptionRapid absorption from gastrointestinal tract. Although the rate of valproate ion absorption may vary with the formulation administered (liquid, solid, or sprinkle), conditions of use (e.g., fasting or postprandial) and the method of administration (e.g., whether the contents of the capsule are sprinkled on food or the capsule is taken intact), these differences should be of minor clinical importance under the steady state conditions achieved in chronic use in the treatment of epilepsy. Food has a greater influence on the rate of absorption of the Depakote tablet (increases Tmax from 4 to 8 hours) than on the absorption of Depakote sprinkle capsules (increase Tmax from 3.3 to 4.8 hours). Furthermore, studies suggest that total daily systemic bioavailability (extent of absorption) is the primary determinant of seizure control.
Volume of distribution
  • 11 L/1.73 m2 [total valproate]
  • 92 L/1.73 m2 [free valproate]
Protein bindingConcentration-dependent, from 90% at 40 µg/mL to 81.5% at 130 µg/mL. Higher than expected free fractions occur in the elderly, in hyperlipidemic patients, and in patients with hepatic and renal diseases. It may also affect the extent of protein binding of other drugs such as phenytoin or carbamazepine.
Metabolism

Valproic Acid is metabolized almost entirely by the liver. In adult patients on monotherapy, 30-50% of an administered dose appears in urine as a glucuronide conjugate. Mitochondrial ß-oxidation is the other major metabolic pathway, typically accounting for over 40% of the dose. Usually, less than 15-20% of the dose is eliminated by other oxidative mechanisms. Less than 3% of an administered dose is excreted unchanged in urine.

SubstrateEnzymesProduct
Valproic Acid
4-ene-Valproic acidDetails
Valproic Acid
5-Hydroxyvalproic acidDetails
Valproic Acid
3-Hydroxyvalproic acidDetails
Valproic Acid
4-Hydroxyvalproic acidDetails
Valproic Acid
Valproic acid β-O-glucuronideDetails
Valproic Acid
Not Available
2-ene-Valproic acidDetails
Valproic Acid
Not Available
(3Z)-2-Propylpent-3-enoic acid (3Z-Ene-VPA)Details
Valproic Acid
Not Available
(3E)-2-Propylpent-3-enoic acid (3E-Ene-VPA)Details
Valproic Acid
Not Available
Valproic acid CoADetails
4-ene-Valproic acid
Not Available
2,4-Diene-VPADetails
4-Hydroxyvalproic acid
Not Available
2-n-Propyl-4-oxopentanoic acidDetails
2-n-Propyl-4-oxopentanoic acid
Not Available
2-Propylsuccinic acidDetails
5-Hydroxyvalproic acid
Not Available
2-Propylglutaric acidDetails
3-Hydroxyvalproic acid
Not Available
3-Oxovalproic acidDetails
2-ene-Valproic acid
Not Available
3-Hydroxyvalproic acidDetails
3-Hydroxyvalproic acid
Not Available
3-Oxovalproic acidDetails
Route of eliminationValproate is metabolized almost entirely by the liver. Less than 3% of an administered dose is excreted unchanged in urine. Mitochondrial ß-oxidation is the other major metabolic pathway, typically accounting for over 40% of the dose.
Half life9-16 hours (following oral administration of 250 mg to 1000 mg)
Clearance
  • 0.56 L/hr/1.73 m2 [plasma clearance, total valproate]
  • 4.6 L/hr/1.73 m2 [plasma clearance, free valproate]
  • 4.8 ± 0.17 L/hr/1.73 m2 [males, unbound clearance]
  • 4.7 ± 0.07 L/hr/1.73 m2 [females, unbound clearance]
ToxicityOral, mouse: LD50 = 1098 mg/kg; Oral, rat: LD50 = 670 mg/kg. Symptoms of overdose may include coma, extreme drowsiness, and heart problems. The safety and tolerability of valproate in pediatric patients were shown to be comparable to those in adults.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9828
Blood Brain Barrier+0.9626
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.7345
P-glycoprotein inhibitor INon-inhibitor0.9695
P-glycoprotein inhibitor IINon-inhibitor0.7405
Renal organic cation transporterNon-inhibitor0.9277
CYP450 2C9 substrateNon-substrate0.8247
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7033
CYP450 1A2 substrateNon-inhibitor0.5447
CYP450 2C9 inhibitorNon-inhibitor0.8174
CYP450 2D6 inhibitorNon-inhibitor0.9397
CYP450 2C19 inhibitorNon-inhibitor0.957
CYP450 3A4 inhibitorNon-inhibitor0.9583
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9364
Ames testNon AMES toxic0.9805
CarcinogenicityNon-carcinogens0.5266
BiodegradationReady biodegradable0.8523
Rat acute toxicity1.8543 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9357
hERG inhibition (predictor II)Non-inhibitor0.9249
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Banner pharmacaps inc
  • Abbott laboratories pharmaceutical products div
  • Catalent pharma solutions llc
  • Par pharmaceutical inc
  • Rp scherer north america div rp scherer corp
  • Usl pharma inc
  • Alpharma uspd inc
  • Apotex inc richmond hill
  • High technology pharmacal co inc
  • Pharmaceutical assoc inc div beach products
  • Sun pharmaceutical industries inc
  • Teva pharmaceuticals usa
  • Vintage pharmaceuticals llc
  • Wockhardt eu operations (swiss) ag
Packagers
Dosage forms
FormRouteStrength
Syruporal50 mg
Injectionintravenous100 mg/mL
Capsule, liquid filledoral250 mg/1
Solutionoral250 mg/5mL
Solutionoral50 mg
Tablet, delayed releaseoral125 mg/1
Tablet, delayed releaseoral250 mg/1
Tablet, delayed releaseoral500 mg/1
Tablet, extended releaseoral250 mg/1
Tablet, extended releaseoral500 mg/1
Capsuleoral125 mg/1
Capsule, coated pelletsoral125 mg/1
Capsule, delayed releaseoral125 mg/1
Tablet, film coated, extended releaseoral250 mg/1
Tablet, film coated, extended releaseoral500 mg/1
Tablet, film coatedoral125 mg/1
Tablet, film coatedoral250 mg/1
Tablet, film coatedoral500 mg/1
Tablet, delayed release particlesoral500 mg/1
Liquidintravenous500 mg
Tablet (enteric-coated)oral125 mg
Tablet (enteric-coated)oral250 mg
Tablet (enteric-coated)oral500 mg
Tablet (extended-release)oral500 mg
Tablet (delayed-release)oral125 mg
Tablet (delayed-release)oral250 mg
Tablet (delayed-release)oral500 mg
Capsuleoral250 mg
Capsule (enteric-coated)oral500 mg
Syruporal250 mg
Injectionintravenous500 mg/5mL
Injection, solutionintravenous100 mg/mL
Capsuleoral250 mg/1
Solutionoral500 mg/10mL
Tabletoral250 mg/1
Prices
Unit descriptionCostUnit
Valproic acid liquid10.2USD g
Depakene 250 mg capsule2.21USD capsule
Valproic acid 250 mg capsule0.79USD capsule
Depakene 250 mg/5ml Syrup0.66USD ml
Novo-Valproic 500 mg Enteric-Coated Capsule0.54USD capsule
Pms-Valproic Acid E.C. 500 mg Enteric-Coated Capsule0.54USD capsule
Apo-Valproic 250 mg Capsule0.27USD capsule
Mylan-Valproic 250 mg Capsule0.27USD capsule
Novo-Valproic 250 mg Capsule0.27USD capsule
Nu-Valproic 250 mg Capsule0.27USD capsule
Pms-Valproic Acid 250 mg Capsule0.27USD capsule
Ratio-Valproic 250 mg Capsule0.27USD capsule
Sandoz Valproic 250 mg Capsule0.27USD capsule
Valproic Acid 250 mg/5ml Syrup0.16USD ml
Valproic acid 250 mg/5 ml syr0.15USD ml
Depakene 50 mg/ml Syrup0.11USD ml
Apo-Valproic 50 mg/ml Syrup0.06USD ml
Pms-Valproic Acid 50 mg/ml Syrup0.06USD ml
Ratio-Valproic 50 mg/ml Syrup0.06USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States65116781999-06-182019-06-18
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point120-130 °CNot Available
water solubility1.3 mg/mLFDA label
logP2.75SANGSTER (1993)
logS-1.86ADME Research, USCD
pKa4.8FDA label
Predicted Properties
PropertyValueSource
Water Solubility2.36 mg/mLALOGPS
logP2.54ALOGPS
logP2.8ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)5.14ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity40.25 m3·mol-1ChemAxon
Polarizability17 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.07 KB)
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, N/A (Annotated)splash10-8z00000000-156413e81733a6236c1fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, N/A (Annotated)splash10-az00000000-a769cafb885b78532cacView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, N/A (Annotated)splash10-tz00000000-46a522b9a26459334f5aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negativesplash10-0z00000000-39a45d4e3201082d9d89View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negativesplash10-z000000000-4ddd957d8c8dc2b1de03View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negativesplash10-0z00000000-6ba582ae102c4721034dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negativesplash10-0z00000000-58d9ba88010f1b370c58View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negativesplash10-ez00000000-2d1032d7e8ac58235b4fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negativesplash10-z000000000-0d39870bc4521a42c50aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negativesplash10-z000000000-3c4e21b69b8877d6df3eView in MoNA
MSMass Spectrum (Electron Ionization)splash10-zc00000000-1a0314ea63d5a3c9bba1View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Daniel Aubert, Francis Blanc, Henri Desmolin, Michel Morre, Lucette Sindely, “Valproic acid preparations.” U.S. Patent US5017613, issued January, 1965.

US5017613
General References
  1. Rosenberg G: The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci. 2007 Aug;64(16):2090-103. Pubmed
  2. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM: Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005 Aug 13-19;366(9485):549-55. Pubmed
  3. Schwartz C, Palissot V, Aouali N, Wack S, Brons NH, Leners B, Bosseler M, Berchem G: Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines. Int J Oncol. 2007 Mar;30(3):573-82. Pubmed
  4. Valentini A, Gravina P, Federici G, Bernardini S: Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther. 2007 Feb;6(2):185-91. Epub 2007 Feb 5. Pubmed
  5. FDA label
External Links
ATC CodesN03AG01
AHFS Codes
  • 28:12.92
PDB Entries
FDA labelDownload (1.41 MB)
MSDSDownload (77.9 KB)
Interactions
Drug Interactions
Drug
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Valproic Acid.
Acetylsalicylic acidThe serum concentration of Valproic Acid can be increased when it is combined with Acetylsalicylic acid.
Aminosalicylic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Aminosalicylic Acid.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Valproic Acid.
AmobarbitalThe serum concentration of Amobarbital can be increased when it is combined with Valproic Acid.
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Valproic Acid.
AtazanavirThe serum concentration of Valproic Acid can be decreased when it is combined with Atazanavir.
BatimastatThe serum concentration of Valproic Acid can be decreased when it is combined with Batimastat.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Valproic Acid.
Bismuth SubsalicylateThe serum concentration of Valproic Acid can be increased when it is combined with Bismuth Subsalicylate.
ButabarbitalThe serum concentration of Butabarbital can be increased when it is combined with Valproic Acid.
ButalbitalThe serum concentration of Butalbital can be increased when it is combined with Valproic Acid.
ButethalThe serum concentration of Butethal can be increased when it is combined with Valproic Acid.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Valproic Acid.
CarbamazepineThe serum concentration of the active metabolites of Carbamazepine can be increased when Carbamazepine is used in combination with Valproic Acid.
ChlorpromazineThe serum concentration of Valproic Acid can be increased when it is combined with Chlorpromazine.
CilastatinThe serum concentration of Valproic Acid can be decreased when it is combined with Cilastatin.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Valproic Acid.
CosyntropinCosyntropin may increase the hepatotoxic activities of Valproic Acid.
DarunavirThe serum concentration of Valproic Acid can be decreased when it is combined with Darunavir.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Valproic Acid.
DihydrocodeineThe serum concentration of Valproic Acid can be increased when it is combined with Dihydrocodeine.
DoripenemThe serum concentration of Valproic Acid can be decreased when it is combined with doripenem.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Valproic Acid.
ErtapenemThe serum concentration of Valproic Acid can be decreased when it is combined with Ertapenem.
EthosuximideThe serum concentration of Valproic Acid can be decreased when it is combined with Ethosuximide.
FelbamateThe serum concentration of Valproic Acid can be increased when it is combined with Felbamate.
FosamprenavirThe serum concentration of Valproic Acid can be decreased when it is combined with Fosamprenavir.
FosphenytoinThe serum concentration of Fosphenytoin can be decreased when it is combined with Valproic Acid.
Gamma Hydroxybutyric AcidThe serum concentration of Gamma Hydroxybutyric Acid can be increased when it is combined with Valproic Acid.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Valproic Acid.
GuanfacineThe serum concentration of Valproic Acid can be increased when it is combined with Guanfacine.
HeptabarbitalThe serum concentration of Heptabarbital can be increased when it is combined with Valproic Acid.
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Valproic Acid.
ImipenemThe serum concentration of Valproic Acid can be decreased when it is combined with Imipenem.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Valproic Acid.
IndinavirThe serum concentration of Valproic Acid can be decreased when it is combined with Indinavir.
IsoflurophateThe serum concentration of Valproic Acid can be decreased when it is combined with Isoflurophate.
LamotrigineThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Lamotrigine.
LopinavirThe serum concentration of Valproic Acid can be decreased when it is combined with Lopinavir.
LorazepamThe serum concentration of Lorazepam can be increased when it is combined with Valproic Acid.
Magnesium salicylateThe serum concentration of Valproic Acid can be increased when it is combined with Magnesium salicylate.
MefloquineThe therapeutic efficacy of Valproic Acid can be decreased when used in combination with Mefloquine.
MeropenemThe serum concentration of Valproic Acid can be decreased when it is combined with Meropenem.
MethohexitalThe serum concentration of Methohexital can be increased when it is combined with Valproic Acid.
MianserinThe therapeutic efficacy of Valproic Acid can be decreased when used in combination with Mianserin.
MinoxidilThe serum concentration of Minoxidil can be increased when it is combined with Valproic Acid.
NelfinavirThe serum concentration of Valproic Acid can be decreased when it is combined with Nelfinavir.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Valproic Acid.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Valproic Acid.
OrlistatThe serum concentration of Valproic Acid can be decreased when it is combined with Orlistat.
OxcarbazepineThe serum concentration of Oxcarbazepine can be decreased when it is combined with Valproic Acid.
PaliperidoneThe serum concentration of Paliperidone can be increased when it is combined with Valproic Acid.
PentobarbitalThe serum concentration of Pentobarbital can be increased when it is combined with Valproic Acid.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Valproic Acid.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Valproic Acid.
PrimidoneThe metabolism of Primidone can be decreased when combined with Valproic Acid.
PromazineThe serum concentration of Valproic Acid can be increased when it is combined with Promazine.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Valproic Acid.
RifampicinThe serum concentration of Valproic Acid can be decreased when it is combined with Rifampicin.
RisperidoneThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Risperidone.
RitonavirThe serum concentration of Valproic Acid can be decreased when it is combined with Ritonavir.
RufinamideThe serum concentration of Rufinamide can be increased when it is combined with Valproic Acid.
Salicylate-sodiumThe serum concentration of Valproic Acid can be increased when it is combined with Salicylate-sodium.
SalsalateThe serum concentration of Valproic Acid can be increased when it is combined with Salsalate.
SaquinavirThe serum concentration of Valproic Acid can be decreased when it is combined with Saquinavir.
SecobarbitalThe serum concentration of Secobarbital can be increased when it is combined with Valproic Acid.
SimeprevirThe serum concentration of Valproic Acid can be decreased when it is combined with Simeprevir.
Sodium oxybateThe serum concentration of Sodium oxybate can be increased when it is combined with Valproic Acid.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Valproic Acid.
TemozolomideThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Temozolomide.
TipranavirThe serum concentration of Valproic Acid can be decreased when it is combined with Tipranavir.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Valproic Acid.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Valproic Acid.
VorinostatValproic Acid may increase the thrombocytopenic activities of Vorinostat.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Valproic Acid.
Food Interactions
  • Avoid alcohol.
  • Do not take with milk.
  • Take with food.

Targets

1. Histone deacetylase 9

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Histone deacetylase 9 Q9UKV0 Details

References:

  1. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM: Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS. 2004 May 21;18(8):1101-8. Pubmed
  2. Michaelis M, Kohler N, Reinisch A, Eikel D, Gravemann U, Doerr HW, Nau H, Cinatl J Jr: Increased human cytomegalovirus replication in fibroblasts after treatment with therapeutical plasma concentrations of valproic acid. Biochem Pharmacol. 2004 Aug 1;68(3):531-8. Pubmed
  3. Kanai H, Sawa A, Chen RW, Leeds P, Chuang DM: Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacogenomics J. 2004;4(5):336-44. Pubmed
  4. Stockhausen MT, Sjolund J, Manetopoulos C, Axelson H: Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br J Cancer. 2005 Feb 28;92(4):751-9. Pubmed
  5. Beutler AS, Li S, Nicol R, Walsh MJ: Carbamazepine is an inhibitor of histone deacetylases. Life Sci. 2005 May 13;76(26):3107-15. Pubmed
  6. Rosenberg G: The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci. 2007 Aug;64(16):2090-103. Pubmed
  7. Kawano T, Akiyama M, Agawa-Ohta M, Mikami-Terao Y, Iwase S, Yanagisawa T, Ida H, Agata N, Yamada H: Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation. Int J Oncol. 2010 Oct;37(4):787-95. Pubmed

2. 4-aminobutyrate aminotransferase, mitochondrial

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
4-aminobutyrate aminotransferase, mitochondrial P80404 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Loscher W: Anticonvulsant and biochemical effects of inhibitors of GABA aminotransferase and valproic acid during subchronic treatment in mice. Biochem Pharmacol. 1982 Mar 1;31(5):837-42. Pubmed
  4. Ha JH, Lee DU, Lee JT, Kim JS, Yong CS, Kim JA, Ha JS, Huh K: 4-Hydroxybenzaldehyde from Gastrodia elata B1. is active in the antioxidation and GABAergic neuromodulation of the rat brain. J Ethnopharmacol. 2000 Nov;73(1-2):329-33. Pubmed
  5. Semba J, Kuroda Y, Takahashi R: Potential antidepressant properties of subchronic GABA transaminase inhibitors in the forced swimming test in mice. Neuropsychobiology. 1989;21(3):152-6. Pubmed
  6. Rosenberg G: The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci. 2007 Aug;64(16):2090-103. Pubmed
  7. Bruni J, Wilder BJ: Valproic acid. Review of a new antiepileptic drug. Arch Neurol. 1979 Jul;36(7):393-8. Pubmed

3. Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial P45954 Details

References:

  1. Ito M, Ikeda Y, Arnez JG, Finocchiaro G, Tanaka K: The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase. Biochim Biophys Acta. 1990 May 16;1034(2):213-8. Pubmed
  2. Bazinet RP, Weis MT, Rapoport SI, Rosenberger TA: Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder. Psychopharmacology (Berl). 2006 Jan;184(1):122-9. Epub 2005 Dec 13. Pubmed

4. 2-oxoglutarate dehydrogenase, mitochondrial

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
2-oxoglutarate dehydrogenase, mitochondrial Q02218 Details

References:

  1. Johannessen CU, Johannessen SI: Valproate: past, present, and future. CNS Drug Rev. 2003 Summer;9(2):199-216. Pubmed

5. Succinate-semialdehyde dehydrogenase, mitochondrial

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Succinate-semialdehyde dehydrogenase, mitochondrial P51649 Details

References:

  1. Johannessen CU, Johannessen SI: Valproate: past, present, and future. CNS Drug Rev. 2003 Summer;9(2):199-216. Pubmed

6. Sodium channel protein

Kind: Protein group

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Sodium channel protein type 1 subunit alpha P35498 Details
Sodium channel protein type 10 subunit alpha Q9Y5Y9 Details
Sodium channel protein type 11 subunit alpha Q9UI33 Details
Sodium channel protein type 2 subunit alpha Q99250 Details
Sodium channel protein type 3 subunit alpha Q9NY46 Details
Sodium channel protein type 4 subunit alpha P35499 Details
Sodium channel protein type 5 subunit alpha Q14524 Details
Sodium channel protein type 7 subunit alpha Q01118 Details
Sodium channel protein type 8 subunit alpha Q9UQD0 Details
Sodium channel protein type 9 subunit alpha Q15858 Details
Sodium channel subunit beta-1 Q07699 Details
Sodium channel subunit beta-2 O60939 Details
Sodium channel subunit beta-3 Q9NY72 Details
Sodium channel subunit beta-4 Q8IWT1 Details

References:

  1. Farber NB, Jiang XP, Heinkel C, Nemmers B: Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol Psychiatry. 2002;7(7):726-33. Pubmed

7. Histone deacetylase 2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Histone deacetylase 2 Q92769 Details

References:

  1. Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, Brill B, Groner B, Bach I, Heinzel T, Gottlicher M: The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 2003 Jul 1;22(13):3411-20. Pubmed
  2. Gottlicher M: Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol. 2004;83 Suppl 1:S91-2. Pubmed

Enzymes

1. Cytochrome P450 2A6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inducer

Components

Name UniProt ID Details
Cytochrome P450 2A6 P11509 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  3. Lexicomp

2. Cytochrome P450 2B6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2B6 P20813 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

3. Cytochrome P450 2C9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  3. Lexicomp

4. Cytochrome P450 3A5

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

5. Prostaglandin G/H synthase 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Prostaglandin G/H synthase 1 P23219 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

6. Cytochrome P450 1A2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

7. Cytochrome P450 2C18

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C18 P33260 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

8. Cytochrome P450 2C19

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

9. Cytochrome P450 2C8

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

10. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

11. UDP-glucuronosyltransferase 1-4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 1-4 P22310 Details

References:

  1. Argikar UA, Remmel RP: Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36. doi: 10.1124/dmd.108.022426. Epub 2008 Oct 6. Pubmed

12. UDP-glucuronosyltransferase 1-8

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 1-8 Q9HAW9 Details

References:

  1. Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH: UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6. Epub 2005 Mar 10. Pubmed

13. UDP-glucuronosyltransferase 1-10

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 1-10 Q9HAW8 Details

References:

  1. Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH: UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6. Epub 2005 Mar 10. Pubmed

14. UDP-glucuronosyltransferase 1-6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 1-6 P19224 Details

References:

  1. Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH: UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6. Epub 2005 Mar 10. Pubmed

15. UDP-glucuronosyltransferase 1-3

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 1-3 P35503 Details

References:

  1. Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH: UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6. Epub 2005 Mar 10. Pubmed
  2. Argikar UA, Remmel RP: Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36. doi: 10.1124/dmd.108.022426. Epub 2008 Oct 6. Pubmed
  3. Chung JY, Cho JY, Yu KS, Kim JR, Lim KS, Sohn DR, Shin SG, Jang IJ: Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600. Epub 2007 Aug 8. Pubmed

16. UDP-glucuronosyltransferase 2B7

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 2B7 P16662 Details

References:

  1. Chung JY, Cho JY, Yu KS, Kim JR, Lim KS, Sohn DR, Shin SG, Jang IJ: Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600. Epub 2007 Aug 8. Pubmed

17. UDP-glucuronosyltransferase 2B15

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 2B15 P54855 Details

References:

  1. Chung JY, Cho JY, Yu KS, Kim JR, Lim KS, Sohn DR, Shin SG, Jang IJ: Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600. Epub 2007 Aug 8. Pubmed

18. UDP-glucuronosyltransferase 1-9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 1-9 O60656 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

Transporters

1. Solute carrier family 22 member 5

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 5 O76082 Details

References:

  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. Pubmed

2. Solute carrier family 22 member 6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 6 Q4U2R8 Details

References:

  1. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H: Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem. 1997 Jul 25;272(30):18526-9. Pubmed

3. Solute carrier family 22 member 8

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 8 Q8TCC7 Details

References:

  1. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, Terasaki T: Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem. 2002 Oct;83(1):57-66. Pubmed
  2. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. Pubmed

4. Monocarboxylate transporter 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Monocarboxylate transporter 1 P53985 Details

References:

  1. Tamai I, Sai Y, Ono A, Kido Y, Yabuuchi H, Takanaga H, Satoh E, Ogihara T, Amano O, Izeki S, Tsuji A: Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J Pharm Pharmacol. 1999 Oct;51(10):1113-21. Pubmed

5. Solute carrier family 22 member 7

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier family 22 member 7 Q9Y694 Details

References:

  1. Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T: Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 03, 2013 14:46